REG - Arecor Therapeutics - Appointment of SVP for Tetris Pharma Ltd

Arecor TherapeuticsAnnouncement

03/01/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240103:nRSC4316Ya&default-theme=true

RNS Number : 4316Y  Arecor Therapeutics PLC  03 January 2024

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR APPOINTS DR HELEN PARRIS AS SENIOR VICE PRESIDENT, COMMERCIAL AND
GENERAL MANAGER OF TETRIS PHARMA LTD

 

Cambridge, UK, 3 January 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, is pleased to announce the appointment of Dr. Helen Parris as Senior
Vice President, Commercial and General Manager of the Group's subsidiary
company, Tetris Pharma Ltd ("Tetris Pharma"), effective Monday 15 January
2024.

 

Helen has over 20 years of scientific, commercial and government affairs
experience across several international biopharmaceutical companies and has
been responsible for launching transformational products and shaping markets
across large pharmaceutical and biotechnology companies. Prior to joining
Tetris Pharma, Helen served as General Manager Northern Markets (UK,
Netherlands and Nordics) at Albireo Pharma, Inc., which was acquired by Ipsen
(Euronext: IPN; ADR: IPSEY) in March 2023, and where she played a key role in
establishing and building the regional affiliate and launching the first
product to market.

 

Previously, Helen held multiple positions at Gilead (NASDAQ: GILD), including
Executive Director EMEA, Global Affairs Regional Lead, and was instrumental in
broadening patient access to treatment. Whilst at Gilead, Helen led the launch
of several transformational drugs, developed critical launch strategies and
expanded commercial opportunities.

 

Helen holds a BSc in Biology from York University, a PhD from Leeds University
and an MBA from Henley Management College.

 

Sarah Howell, Chief Executive Officer at Arecor, said: "I am delighted to
welcome Helen to Tetris Pharma and the Arecor Group as a key member of our
leadership team. Helen's proven track record in bringing products to market
and growing sales will be key as we continue the roll-out of Ogluo® across
the UK and Europe. Ogluo® is an important treatment for people with diabetes
and their caregivers that can provide them with the confidence to manage
severe hypoglycaemic events and, under Helen's leadership, Tetris Pharma is
even better positioned for the continued adoption of this key product in a
c.£100 million market. Not only will this deliver a revenue stream but a
successful commercial distribution platform through Tetris Pharma is highly
complementary to our existing specialty hospital products business and has
significant growth potential, providing Arecor with the capability to take
selected products to market in the UK and Europe."

 

 Dr. Helen Parris, Senior Vice President, Commercial and General Manager at
Tetris Pharma, commented: "I am thrilled to be joining the team at Tetris
Pharma to support the development of the company's lead product, Ogluo®, and
continue its accelerated roll-out across Europe. Ogluo(®) meets a key need
for people living with diabetes at risk of severe hypoglycaemia, a condition
which can have a profound effect on the everyday lives of those with diabetes
and their caregivers. I look forward to leading the company as it continues to
expand its pan-European presence."

 

-ENDS-

 

 

 

For more information, please contact:

 

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville      Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXFAEALLEFA